Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice

In a cohort of 321,304 patients with type 2 diabetes and atherosclerotic cardiovascular disease, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) increased from January 2018 to March 2021.

• The proportion of patients using SGLT2i rose from 5.8% to 12.9%, while GLP-1 RA usage increased from 6.9% to 13.8%.
• Combined use of either SGLT2i or GLP-1 RA grew from 11.4% to 23.2% during the study period.
• Patients using SGLT2i or GLP-1 RA were generally younger and less frequently hospitalized in the previous year.
• The demographics of treated and untreated patients were similar in terms of race, ethnicity, and outpatient health care utilization.
• Despite the increase in usage, less than a quarter of individuals with atherosclerotic cardiovascular disease and type 2 diabetes were taking SGLT2i or GLP-1 RA.

AI simplified